GRALGRAIL, Inc.
Services-Medical Laboratories
- Revenue
- $147M
- 17% YoY
- Operating margin
- -382.0%
- 78% YoY
- EBITDA
- −$544M
- 75% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired40% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $93M | $126M | $147M | 17% |
| Operating income | −$1.5B | −$2.2B | −$562M | 74% |
| Net income | −$1.5B | −$2.0B | −$408M | 80% |
| Operating cash flow | −$596M | −$577M | −$299M | 48% |
| Capex | $13M | $5M | $909K | 83% |
| Stock-based comp | $97M | $86M | $58M | 32% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $14M · 22
- Net
- −$14M
Pay vs performance
No pay-versus-performance disclosure yet.